Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma [0.03%]
Child-Pugh B期不可切除肝细胞癌患者乐伐替尼治疗减量/中断的不良事件分析
Michio Kimura,Hiroki Asano,Eiseki Usami et al.
Michio Kimura et al.
Introduction: We aimed to compare the safety of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh A (CP-A) and Child-Pugh B (CP-B) and to determine the adverse ...
Exploration of current pharmacy practice in cardio-oncology: Experiences & perspectives [0.03%]
心血管肿瘤学中当前药房实践的探索：体验与观点
Alisha Merali,Maria Anwar,Jamie M Boyd et al.
Alisha Merali et al.
Introduction: Cardiovascular complications can occur in oncology patients secondary to certain cancer therapies. Pharmacists are involved in the care of oncology patients who are at risk of or experiencing cardiotoxicity ...
Medication errors in an oncology inpatient setting in India-Audit by clinical pharmacists [0.03%]
印度肿瘤住院患者中的药物错误-临床药师审核
Akshay Chaudhari,Akshay Mule,Priti Dhande
Akshay Chaudhari
Background: Good clinical practices and strict vigilance are needed, especially for patients receiving chemotherapy. Regular audits using a specially developed tool need to be conducted in the oncology wards to identify l...
Effectiveness of antiemetic in reducing chemotherapy-induced nausea and vomiting in adult patients; An oncology center experience [0.03%]
止吐药物在减少成人化疗引起的恶心和呕吐方面的有效性；一个肿瘤中心的体验
Haya F Al-Salloum,Hayat Eid Al-Harbi,Ahmed Abdelazeem
Haya F Al-Salloum
Introduction: Chemotherapy-induced nausea and vomiting (CINV) are two serious adverse effect of cancer chemotherapy. The objectives of this study are to assess patient satisfaction with antiemetics prescribed, incidence o...
Knowledge and practices about safe handling regarding the risk of exposure to antineoplastic drugs for caregivers in compounding units and in operating rooms performing HIPEC/PIPAC [0.03%]
关于抗癌药物暴露风险安全处理的知识和实践调查：配液室和进行HIPEC/PIPAC手术的医务人员
Clémence Delafoy,Hubert Benoist,Alex Patin et al.
Clémence Delafoy et al.
Introduction: Ever since the late 1970s, occupational exposure associated with the handling of antineoplastic drugs (ADs) in the healthcare environment has been highlighted and demonstrated. Contamination was detected in ...
Cyclophosphamide exposure via sweat of patients receiving CHOP therapy [0.03%]
接受CHOP治疗的患者的汗液中的环磷酰胺暴露量
Maho Miyazawa,Rina Yamashita,Yui Ichinohe et al.
Maho Miyazawa et al.
Introduction: "Secondary exposure to anticancer drugs" refers to exposure to anticancer drugs after chemotherapy via the patient's urine and other excretions. The necessity of countermeasures against secondary exposure to...
Implementation of pharmaceutical care service to elderly cancer patients in a tertiary care hospital in South India [0.03%]
在印度南方一家三级护理医院中对老年癌症患者实施药学照护服务
Shaik Fariya,Priya Jovita Mary Martin Daniel,John Stephen Raj et al.
Shaik Fariya et al.
Purpose: The goal of this study is to identify drug-related problems (DRPs) for elderly cancer patients receiving chemotherapy by implementing pharmaceutical care services. ...
Imatinib plasma levels in patients with gastrointestinal stromal tumour under routine clinical practice conditions [0.03%]
常规临床实践中胃肠间质瘤患者伊马替尼的血药浓度研究
Betel Del Rosario García,José Alberto Morales Barrios,Josefina Cruz Jurado et al.
Betel Del Rosario García et al.
Objectives: Imatinib is the first therapeutic option for the treatment of unresectable or metastatic gastrointestinal stromal tumours. Previous studies have shown an improvement in patient survival rates following the use...
Paula Ruiz-Briones,Vicente Escudero-Vilaplana,Roberto Collado-Borrell et al.
Paula Ruiz-Briones et al.
Introduction: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). It has demonstrated better result...
Pneumonitis associated with bortezomib in a patient with multiple myeloma [0.03%]
多发性骨髓瘤患者出现与硼替佐米相关的肺炎性疾病
Taha Ulutan Kars,Osman Yaşkıran,Özcan Çeneli
Taha Ulutan Kars
Introduction: Bortezomib, which is widely used in the treatment of multiple myeloma (MM), is a proteasome inhibitor and acts by inducing apoptosis. Bortezomib has many side effects, mainly hematological, neurological, and...